The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Treatment options for patients with Hodgkin lymphoma who progress after brentuximab vedotin
Alex Herrera, MD, City of Hope, Duarte, CA, discusses treatment options for patients with Hodgkin lymphoma (HL) who progress after brentuximab vedotin or PD1 blockade, including epigenetic modifying agents, antibody drug conjugates (ADCs) such as camidanlumab tesirine, and other cellular therapies. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
